Ivabradine
Check Drug InteractionsCheck known drug interactions.
Check Drug InteractionsIvabradine Prescribing Information
Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated:
- To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.
Adult patients
● Starting dose is 2.5 (vulnerable adults) or 5 mg twice daily with food. After 2 weeks of treatment, adjust dose based on heart rate. The maximum dose is 7.5 mg twice daily.
Tablets
Ivabradine tablets 5 mg: Light salmon-colored, capsule-shaped, film-coated scored tablet debossed with "I5" divided by score on one side and plain on other side. The tablet is scored and can be divided into equal halves to provide a 2.5 mg dose.
Ivabradine tablets 7.5 mg: Light salmon-colored, round-shaped, film-coated tablet debossed with "I" on one side & 7.5 on other side.
- Lactation: Breastfeeding not recommended.
Ivabradine tablets are contraindicated in patients with:
- Acute decompensated heart failure
- Clinically significant hypotension
- Sick sinus syndrome, sinoatrial block or 3rddegree AV block, unless a functioning demand pacemaker is present
- Clinically significant bradycardia [see Warnings and Precautions (5.3)]
- Severe hepatic impairment [see Use in Specific Populations (8.6)]
- Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions (7.3)]
- Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions (7.1)]
- Fetal toxicity: Females should use effective contraception.
- Monitor patients for atrial fibrillation.
- Monitor heart rate decreases and bradycardia symptoms during treatment.
- Not recommended in patients with 2nddegree AV block.
We receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available